other material
confidence high
sentiment positive
materiality 0.80
Reviva completes enrollment in Phase 3 RECOVER study for brilaroxazine in schizophrenia; topline data expected Oct 2023
REVIVA PHARMACEUTICALS HOLDINGS, INC.
- Enrollment of 402 patients across US (~60%), Europe (~10%), and Asia (~30%) in pivotal Phase 3 RECOVER trial.
- Topline efficacy and safety data for RECOVER expected in October 2023.
- Over 50% of patients enrolled in 1-year open-label extension study; completion expected in Q3 2024.
- Primary endpoint: change in PANSS total score from baseline to Day 28 vs placebo.